Intellia Therapeutics Inc is trading 13.5% up today at $14.77 as investors react to fresh bullish research from Zacks ahead of the company's upcoming earnings report.
- Zacks Investment Research highlighted that Intellia is expected to post a narrower quarterly loss of $0.92 per share and is statistically likely to beat consensus EPS estimates, providing support for the stock's upside.
- The significant move comes despite a mixed performance in the broader market and follows recent capital raise activity conducted earlier in 2026.